ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1415	National Cancer Institute	Html	en	Grief, Bereavement, and Coping With Loss (PDQ®)–Patient Version	Expert-reviewed report about grief, bereavement, and feelings of loss in survivors of someone who has died of cancer. Grief in children is also discussed.	normal grief process 0.471417 Common grief reactions 0.532686 grief pattern 0.454756 bereaved person moves 0.399208 family member 0.390974 PDQ cancer information 0.489866 unexpected loss 0.387668 loss 0.666269 children 0.561087 typical grief response 0.466341 PDQ Grief 0.446846 clinical trials 0.426876 grief 0.931776 anticipatory grief 0.60415 cancer information summary 0.442789 social support 0.46161 clinical trial 0.441424 younger bereaved people 0.426523 family members 0.386464 Grief bursts 0.441053 weight loss 0.372081 bereaved people 0.499808 severe grief 0.457196 difficult grief 0.440844	NCI PDQ cancer 0.383634 grief reactions 0.581886 person 0.556278 grief symptoms 0.442678 deceased person 0.373691 child 0.531789 distress 0.378808 normal grief 0.541883 death 0.826955 Chronic grief 0.43943 Cancer Information Service 0.369255 complicated grief 0.451713 National Cancer Institute 0.448538 health care 0.379094 grief process 0.5341 Palliative Care Editorial 0.392193 new treatment 0.370063 different cultures 0.372731 Care Editorial Board 0.393341 people 0.580964 way 0.395094 grief treatment 0.44457 comprehensive cancer information 0.368169 depression 0.378859	CLICK HERE
1416	National Cancer Institute	Html	en	Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer.	relapsed ovarian cancer 0.50784 recurrent epithelial ovarian 0.499159 ovarian cancer symptom 0.524517 gynecologic cancer intergroup 0.468129 epithelial ovarian carcinoma 0.585917 chemotherapy 0.476196 Engl J Med 0.538958 advanced ovarian cancer 0.684932 advanced epithelial ovarian 0.546935 ovarian cancer FIGO 0.514859 ovarian cancer. 0.501481 [PUBMED Abstract] 0.522867 primary peritoneal cancer 0.467281 ovarian cancer patients 0.574798 ovarian cancer trials 0.513542 Ovarian Cancer Registry 0.525648 ovarian cancer 0.976385 oncology group study 0.500359 advanced ovarian epithelial 0.508108 ovarian carcinoma 0.617715 Hereditary ovarian cancer 0.541701 Natl Cancer Inst 0.533435 Clin Cancer Res 0.471625 Gynecol Oncol 0.499118 ovarian carcinoma patients 0.50527	et al. 0.626141 gynecologic oncology group 0.583453 Lancet Oncol 0.480848 refractory ovarian cancer 0.508349 ovarian cancer—is 0.495704 ovarian cancers 0.496625 II-IV ovarian cancer 0.51385 advanced ovarian carcinoma 0.5343 ovarian epithelial cancer 0.539908 residual ovarian cancer 0.518325 epithelial ovarian cancer 0.803483 ovarian cancer susceptibility 0.533409 Brady MF 0.481715 sporadic ovarian cancer 0.521614 Abstract 0.644778 Clin Oncol 0.718243 platinum-sensitive ovarian cancer 0.536106 BRCA2-associated ovarian cancer 0.521842 recurrent ovarian cancer 0.527704 serous ovarian cancer 0.529665 Ovarian Neoplasm Group 0.493177 advanced-stage ovarian cancer 0.537713 ovarian cancer screening 0.523447 ovarian cancer syndrome 0.536708	CLICK HERE
1532	National Cancer Institute	Html	en	714-X (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of 714-X as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	peer-reviewed scientific journals 0.887587 follow-up treatment 0.710806 cancer cell growth 0.791188 clinical drug research 0.768994 transplanted lymphoma cells 0.825998 camphor-containing compound 0.745221 -dependent breast cancer 0.78236 Cancer Terms 0.744215 ammonia chloride moiety 0.76714 well-designed clinical trials 0.748928 IND application process 0.779791 normal cellular metabolism 0.86297 cancer information summary 0.831041 markets 714-X worldwide 0.83392 breast adenocarcinoma cells 0.816142 conventional light microscope 0.751864 high-magnification dark-field microscope 0.762305 single daily injection 0.759423 local radiation therapy 0.743305 Investigational New Drug 0.768167 estrone sulfatase activity 0.749881 radiation therapy 0.757461 usual treatment cycle 0.783702 immune system cells 0.780568 dead cells 0.766188	lymphoma tumor models 0.74615 treatment cycles 0.709107 peer-reviewed scientific journal 0.752325 breast cancer cells 0.935858 714-X states 0.744286 tumor cells 0.75621 camphor component 0.757515 secrete growth hormones 0.755571 cancer cells 0.999087 malignant cells 0.759464 lymphosarcoma tumor model 0.750284 714-X treatment. 0.746291 human breast cancer 0.781637 privately funded laboratory 0.780536 normal cells 0.757341 714-X state 0.740311 animal studies 0.738772 cancer development 0.726298 714-X reportedly works 0.811434 3-day rest period 0.75559 natural killer cells 0.815748 quality control procedures 0.767937 camphor vapors 0.863518 Numerous trace elements 0.765609	CLICK HERE
1667	National Cancer Institute	Html	en	Pituitary Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of pituitary tumors.	cancer treatment 0.407234 dexamethasone suppression test 0.394248 pituitary tumors 0.908358 body 0.454559 PDQ cancer information 0.487589 clinical trials 0.725513 cancer information summary 0.446379 clinical trial 0.553145 Invasive pituitary adenomas 0.455827 pituitary tumor 0.646868 treatment clinical trial 0.392398 PDQ Adult Treatment 0.388468 transsphenoidal surgery 0.460842 symptoms 0.386795 NCI PDQ cancer 0.400275 radiation therapy 0.593266 Treatment Editorial Board 0.409955 general cancer information 0.38362 treatment 0.554395 Pituitary Tumors Treatment 0.478882 magnetic resonance imaging 0.396976 hormones 0.440574 non-functioning pituitary tumor 0.50102 pituitary adenomas 0.476474	cancer cells 0.443241 pituitary gland 0.710758 Cancer Information Service 0.384842 pituitary carcinomas 0.478569 hormone 0.451928 treatment clinical trials 0.429229 National Cancer Institute 0.477993 spinal cord 0.43789 growth hormone 0.42514 lower sex drive 0.403907 new treatment 0.437528 drug therapy 0.42565 stereotactic radiation surgery 0.403899 Non-functioning pituitary tumors 0.494237 Benign pituitary adenomas 0.455748 nuclear magnetic resonance 0.398799 thyroid-stimulating hormone 0.404707 extra hormones 0.398825 cancer clinical trials 0.398461 recurrent pituitary tumor 0.483709 cancer information summaries 0.383614 functioning pituitary tumor 0.497093 comprehensive cancer information 0.383142 cancer 0.645719	CLICK HERE
1870	National Cancer Institute	Html	es	Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario.	germ-cell tumors 0.421459 germ-cell tumors with 0.411803 Obstet Gynecol 0.406415 ovarian germ 0.634072 malignant germ 0.435096 endodermal sinus tumor 0.403615 cell tumors treated 0.404749 Liao SY 0.410388 Adjuvant therapy 0.410358 Gershenson DM 0.467949 Current therapy 0.403318 Williams SD 0.494559 tumores malignos mixtos 0.404882 Hacker NF 0.402853 Instituto Nacional 0.403668 high-dose chemotherapy 0.403104 or etoposide 0.404727 DiSaia PJ 0.408704 Moore DH 0.407371 University Medical Center 0.403543 quimioterapia postoperatoria 0.403765 Gynecol Oncol 0.453558 pacientes jóvenes 0.408368 lavados peritoneales 0.410402 New York University 0.403494	Icb Tumor 0.403092 gynecologic oncology group 0.703201 Blessing JA 0.51199 Birch R 0.404259 estadio iv 0.424378 Einhorn LH 0.40484 Dembo AJ 0.402909 estadio ia 0.408575 ovary with 0.410468 Morris M 0.407706 with advanced germ 0.403782 IIIa Tumor 0.403067 York University Medical 0.403528 Intern Med 0.411687 second-look laparotomy 0.431921 Clin Oncol 0.539728 estadio iii 0.41476 cell tumors using 0.405334 tumor macroscópico 0.402814 Oncology Group Study 0.403519 germ cell tumors 0.985883 histerectomía abdominal 0.412918 Cangir A 0.408111 cell tumors with 0.436879	CLICK HERE
1942	National Cancer Institute	Html	es	Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica.	French-American-British Cooperative Leukaemia 0.312371 leucemia mieloide 0.341853 myelomonocytic leukaemia 0.397359 myelomonocytic leukemia with 0.326213 platelet-derived growth factor 0.354049 with juvenile chronic 0.315892 Arber DA 0.312178 health organization classification 0.3281 Leukemia Group 0.315441 genes platelet-derived growth 0.312347 with juvenile 0.340061 chronic myeloid leukemia 0.336615 myelomonocytic leukemia 0.944712 leucemia mielomonocítica 0.387953 chronic myelomonocytic leukemia 0.819447 differentiating myelomonocytic leukemia 0.320578 Beran M 0.312167 World Health Organization 0.355665 neoplasias mielodisplásicas 0.314258 stem cell transplantation 0.313202 chronic myelogenous leukemia 0.364294 Germing U 0.362762 myeloproliferative disorders 0.313394 cases with chronic 0.311538 Leuk Lymphoma 0.332534	myelomonocytic leukemia from 0.33992 chronic myelomonocytic leukaemia 0.386185 juvenile chronic myelogenous 0.347073 marrow transplantation 0.341155 Organización Mundial 0.317633 chronic myeloid 0.357031 Differentiating juvenile myelomonocytic 0.319715 myeloid neoplasms 0.336696 bone marrow transplantation 0.325127 Bennett JM 0.319603 cromosoma filadelfia 0.337822 recuento plaquetario 0.325577 juvenile myelomonocytic leukaemia 0.339361 juvenile myelomonocytic leukemia 0.545157 chronic myeloid leukaemias 0.320258 Clin Oncol 0.32115 Orazi A 0.343564 Cooperative Leukaemia Group 0.311788 atypical chronic 0.319445 características clínicas 0.316309 trastornos mieloides 0.311632 leucemia mieloide aguda 0.316238 with chronic myelomonocytic 0.340508 Emanuel PD 0.350668	CLICK HERE
1946	National Cancer Institute	Html	es	Tratamiento del neuroblastoma (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del neuroblastoma.	glándula tiroides 0.633074 posibles efectos tardíos 0.641796 siguientes procedimientos 0.632822 células madre 0.931788 gen alk 0.612181 siguientes especialistas 0.624871 yodo 131-mibg 0.744725 vía oral 0.649411 rayos x 0.630232 enlace drugs approved 0.631928 estadios 2A 0.624814 niño ayuda 0.632627 ondas sonoras 0.629873 riesgo intermedio 0.674697 efectos tardíos 0.896983 cáncer.ampliar aspiración 0.633221	National Cancer Institute 0.612675 IRMN).Ampliar Imágenes 0.62564 siguientes tratamientos 0.624353 menor producción 0.628805 Instituto Nacional 0.623964 PDQ Tratamiento 0.634123 determinados cambios 0.611022 alta potencia 0.625499 presente sección 0.614217 nuevos tipos 0.61878 sistema nervioso central 0.655496 Physician Data Query 0.650241 siguientes pruebas 0.680017 siguientes estadios 0.629707 siguientes trastornos 0.624626	CLICK HERE
2064	National Cancer Institute	Html	es	Exposición al asbesto y el riesgo de cáncer	Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información.	técnicos profesionales automotrices 0.5421 gen bap1 0.530949 que familiares de trabajadores 0.533144 normas descritas 0.532666 largo plazo 0.526581 Protección Ambiental 0.672505 World Trade Center 0.546459 principal dependencia 0.532045 Ground Zero 0.529197 derrames pleurales benignos 0.558277 Salud Ocupacional 0.584399 asbesto crisótilo 0.987156 trabajadores portuarios 0.606054 Instituto Nacional 0.563708 menores riesgos 0.533274 Trabajo de EE 0.535904 Employment Standards Administration 0.548898 titulado current best practices 0.543841 Mine Safety 0.535362 sustancias tóxicas 0.635631 siglo xix 0.53032 distintos tipos 0.525229 Estados Unidos 0.992615 automotriz usa 0.531695 Public Affairs 0.529764	serios problemas 0.529441 Environmental Protection Agency 0.815767 línea telefónica tsca 0.556811 Preventing Asbestos Exposure 0.544747 Product Safety Commission 0.67091 Information Division 0.52746 Occupational Safety 0.586355 asbesto causa 0.952053 cuánto tiempo 0.527545 en la mucosidad 0.531534 a las personas 0.529484 posibles peligros 0.5266 Health Administration 0.652906 Consumer Product Safety 0.672282 causa dificultad 0.530297 sumamente bajo. Los fabricantes 0.528798 mejores prácticas 0.574094 Clutch Repair Workers 0.544379 Veterans Affairs 0.528386 Torres Gemelas 0.52642 Compensation Programs 0.5287 Disease Registry 0.526245 Toxic Substances 0.526971 Segunda Guerra Mundial 0.550565	CLICK HERE
3444	National Cancer Institute	Html	es	Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe.	Ramadas K 0.326456 Sankaranarayanan R 0.337876 accessed march 0.331249 Zhang L 0.310727 Clinical Preventive Services 0.308765 Interim results from 0.307724 Sin embargo 0.381657 Kerr AR 0.312561 American Cancer Society 0.427439 Early findings from 0.308051 CA Cancer 0.323169 cluster randomized controlled 0.308479 oral pre-malignant 0.326412 oral cancer 0.913191 Preventive Services Task 0.376173 Instituto Nacional 0.317765 Cancer Res 0.323621 Human papillomavirus infection 0.307515 PDQ Exámenes 0.32226 oral cancer screening 0.566684 Estados Unidos 0.310609 Morton TH Jr 0.307383 Morton TH 0.311837 Epstein JB 0.323025 Database Syst Rev 0.307163	visual screening 0.315772 screening with 0.315479 upper aerodigestive tract 0.307566 SEER Cancer Statistics 0.324889 Cancer Society guidelines 0.325639 Trivandrum Oral Cancer 0.343561 carcinoma versus lesiones 0.311231 Jacob BJ 0.31089 potentially malignant disorders 0.308445 Cancer Facts 0.324242 Long term effect 0.3078 adjacent to clinically 0.307949 Oral Oncol 0.526329 oral verrucous 0.325426 National Cancer Institute 0.351683 center grapples with 0.307601 Oral Pathol Med 0.361585 Screening Study Group 0.316915 Am Dent Assoc 0.308416 Services Task Force 0.375429 Fluorescence visualization detection 0.308258 detección versus atención 0.319469 Brief Evidence Update 0.307856 Poh CF 0.312257	CLICK HERE
3602	National Cancer Institute	Html	en	Improved Strategies for Cancer Prevention and Early Detection	The prevention of cancer and the development of more effective strategies to detect cancer precursors and early stage cancers, when treatment may be most effective, remain critical goals.	cancer treatment 0.540152 anal cancer incidence 0.625627 noncervical cancers 0.552703 preventive HCV vaccine 0.546412 research 0.535928 HPV-positive oropharyngeal cancers 0.555563 cancer biomarker discovery 0.573956 cancer develops 0.60048 cancer biomarker development 0.580329 early pancreatic disease 0.537001 smear-based cervical cancer 0.616538 chronic HCV infection 0.559892 colorectal cancer 0.576235 patients 0.541815 cervical cancer screening 0.699176 cervical cancers 0.57226 cervical cancer 0.761077 HPV vaccine program 0.571212 chronic HBV infection 0.541902 cancers 0.616554 HPV-positive oropharyngeal cancer 0.594068 oncogenic HPV types 0.574039 infectious EBV particles 0.546363 invasive anal cancer 0.592328 United States 0.811567	HCV infection 0.652225 pancreatic cancer precursor 0.587151 percent 0.591951 transfusion-related HCV infection 0.564422 pancreatic cancer 0.645751 precursor lesions 0.541991 common cancer 0.538917 pancreatic cancer cells 0.595973 virus-like particles 0.540706 early cancer detection 0.576023 disease 0.540607 healthy donors 0.556987 persistent HPV infection 0.586925 breast cancer 0.583768 liver cancer mortality 0.588652 late-stage cancer 0.546609 HPV infection 0.707275 cancer risk 0.57351 lung cancer incidence 0.625104 cancer 0.986132 liver cancer 0.648599 Earlier cancer detection 0.569503 EBV infection 0.614356 cancer incidence 0.636488	CLICK HERE